MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE CARDIOVASCULAR RISK STRATIFICATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB: DATA FROM THE OCTAVE CLINICAL PROGRAMME

Stefan Schreiber  1     David T. Rubin  2     Hon Ho Yu  3     Irene Modesto  4     Xiang Guo  5     Chinyu Su  5     Kenneth Kwok  5     Hyejin Jo  5     Yan Chen  5     Arne Yndestad  6     Walter Reinisch  7     Marla C. Dubinsky  8    
1 University Hospital Schleswig-Holstein, Kiel, Germany
2 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, United States
3 LKS Institute of Health Science, Chinese University of Hong Kong, Hong Kong, China
4 Pfizer Inc, New York, United States
5 Pfizer Inc, Collegeville, United States
6 Pfizer Inc, Oslo, Norway
7 Medical University of Vienna, Vienna, Austria
8 Icahn School of Medicine at Mount Sinai, New York, United States

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing